Rapid Micro Biosystems helps businesses accelerate and automate their microbial quality control testing. The company has added new dates for their hands-on workshops in Bedford, Massachusetts. These hands on sessions allow microbial quality control specialists to speak directly with representatives of Rapid Micro Biosystems and interact with the new technology. Attendees learn the challenges impacting the adoption of rapid methods and how the Growth Direct™ technology addresses those challenges. Sessions are interactive and a full agenda is posted at the Rapid Micro Biosystems website.
Click here for dates and details >>
|
|
|
|
|
|
|
|
|
|
|
|
Pfizer Inc. has announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.
Read the full story >>
|
|
 |
|
|
|
|
|
|
|
|
|
|
Date: Wednesday 14 November 2012
Time: 3pm GMT
Length: 1 hour
Rapid microbial testing methods in quality control continue to gain acceptance in pharmaceutical manufacturing, but most companies continue to use manual, traditional methods. The ability to uncover results in less time than traditional methods provides compelling benefits to manufacturers. These benefits can be realised in environmental monitoring, sterility testing, water and bioburden testing.
Learn from experts where rapid technologies, like the Growth Direct™ System can have an impact on microbial quality control and ultimately manufacturing.
Attendees of the event will learn:
* The limitations of the traditional methods
* The importance of non-destructive testing
* The benefits of automated, rapid detection
Register now >>
|
Conferences, events & exhibitions:
Flow Chemistry Asia 2012
25 - 26 October 2012 Singapore
QbD Lifecycle Management for Analytical Methods
25 - 26 October 2012 London, UK
Flow Chemistry India
29 October 2012 Mumbai, India
Indian Lab Automation 2012
30 - 31 October 2012 Mumbai, India
PEGS Europe 2012
6 - 8 November 2012 Vienna, Austria
LAB INNOVATIONS 2012
7 - 8 November 2012 Birmingham NEC, UK
1st International Genomics Research Asia
13 - 14 November 2012 Daejong, South Korea
FoodPharma Tech Herning 2012
13 - 15 November 2012 Herning, Denmark
qPCR Symposium
13 - 16 November 2012 Daejeon, South Korea
CMC Regulatory Compliance for Biopharmaceuticals and Biologics
15 - 16 November 2012 Dublin, Ireland
 IFPAC 2013
22 - 25 January 2013 Maryland, USA
|
|
Pharmaceuticals: Global Industry Almanac
The global pharmaceuticals market grew by 3.6% in 2010 to reach a value of $733,104.8 million. In 2015, the global pharmaceuticals market is forecast to have a value of $981,050.8 million, an increase of 33.8% since 2010.
The “Patent Cliff”: How Pfizer has responded to the loss of its best-selling drug
The global pharmaceuticals market was worth $733bn in 2010. With the patents of many of the world’s best-selling drugs expiring, the market is currently in the middle of a “patent cliff”. This Case Study looks at the various routes companies are taking in order to minimize the adverse effects caused by this “patent cliff”.
OTC Pharmaceuticals: Global Industry Almanac 2011
OTC Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Johnson & Johnson Case Study: Remicade, a Biotech Blockbuster
Remicade is a drug used in treating a variety of immune system diseases, and its active ingredient is produced through biotechnology. Johnson & Johnson reported Remicade sales of $4.6bn in 2010, and the drug is the best-selling “biologic” in the world. This case study examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market.
|
|
|
